Fulgent Genetics Inc (FLGT)

$19.27 -0.28 (-1.43%)
Market Cap 586.66M
Revenue (ttm) 283.47M
Net Income (ttm) -42.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.07%
Debt to Equity Ratio 0.00
Volume 203,000
Avg Vol 295,258
Day's Range N/A - N/A
Shares Out 30.44M
Stochastic %K 8%
Beta 1.03
Analysts Sell
Price Target $22.67

Company Profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer serv...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 626 350 0537
Fax: 626 454 1667
Address:
4399 Santa Anita Avenue, El Monte, United States
jf152
jf152 Jul. 2 at 8:56 PM
$FLGT Where is $18???
1 · Reply
jf152
jf152 Jun. 28 at 3:27 PM
$FLGT where is this $18?
0 · Reply
Sexydream
Sexydream Jun. 23 at 1:43 PM
$FLGT 18s coming today. 17.50 very shortly after that. It will settle around low 17s/high 16s.
1 · Reply
AlexBo6
AlexBo6 Jun. 21 at 11:27 AM
$FLGT #Bullish , hell yeh..
0 · Reply
Sexydream
Sexydream Jun. 20 at 3:51 PM
$FLGT 19s are here. 17s coming soon folks. Will fill the 17.50 gap.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 17 at 12:25 PM
$FLGT Fulgent not mentioned here but it is a huge potential market. Not sure how much or when the newer ADC targeted drugs will also be used though. https://www.globenewswire.com/news-release/2025/03/27/3050697/28124/en/The-Global-Market-for-Paclitaxel-Injections-Presents-an-11-17-Billion-Revenue-Opportunity-by-2029-Analysis-of-Key-Players-Pfizer-BMS-Fresenius-Kabi-Oncology-Abbott-Labs-and-Viatris.html
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:50 PM
$FLGT The last thing I will say is that, yes, as the guys imply below, canceling the forward agreement does feel bullish. We will see.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:41 PM
$FLGT I wish Ming never entered into those forward agreements in the first place. Because he perhaps knew the likely future sequence of events regarding the fold-in of Pharma, and its eventual downward effect on the stock price. In my opinion, while legal, it just felt a bit like a conflict of interest. And calling his trust the ‘Dynasty Trust’ seems a little overbearing too.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:30 PM
$FLGT In Nov 2022, Fulgent paid to bring Pharma back into Fulgent Genetics. Remember that Ming had another agreement earlier, in June 2022 where his Trust received $44M for pledging 1M shares. Maybe ‘fleeced’ is the wrong word but Ming did ‘win’ vs. the bank.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:20 PM
$FLGT What you guys are missing is that Ming’s trust received $29M up front in cash from the bank in creating that Sep 2022 agreement. Ming totally fleeced the bank by canceling the agreement now for just $16.4M.
1 · Reply
Latest News on FLGT
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

Jul 10, 2025, 4:05 PM EDT - 3 days ago

Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out

Jun 10, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 5 weeks ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect

Jun 5, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation

Jun 4, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 5 weeks ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect

May 30, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 6 weeks ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

May 24, 2025, 9:19 PM EDT - 7 weeks ago

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

May 19, 2025, 8:11 AM EDT - 7 weeks ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

May 2, 2025, 12:27 PM EDT - 2 months ago

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

Fulgent Reports First Quarter 2025 Financial Results

May 2, 2025, 7:00 AM EDT - 2 months ago

Fulgent Reports First Quarter 2025 Financial Results

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Apr 10, 2025, 4:05 PM EDT - 3 months ago

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 3 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Mar 20, 2025, 5:46 AM EDT - 4 months ago

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Feb 28, 2025, 11:57 AM EST - 4 months ago

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:00 AM EST - 4 months ago

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Feb 6, 2025, 4:05 PM EST - 5 months ago

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Feb 4, 2025, 4:00 PM EST - 5 months ago

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Dec 24, 2024, 1:25 AM EST - 7 months ago

Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 2:07 AM EST - 8 months ago

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Fulgent Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 8 months ago

Fulgent Reports Third Quarter 2024 Financial Results

Fulgent to Participate in Upcoming Conferences

Nov 5, 2024, 8:00 AM EST - 8 months ago

Fulgent to Participate in Upcoming Conferences

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Oct 31, 2024, 8:00 AM EDT - 9 months ago

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Oct 17, 2024, 4:05 PM EDT - 9 months ago

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25, 2024, 11:32 AM EDT - 10 months ago

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 9, 2024, 12:05 PM EDT - 10 months ago

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 10:24 AM EDT - 1 year ago

Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript

Fulgent Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Fulgent Reports Second Quarter 2024 Financial Results

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

Jun 10, 2024, 1:00 AM EDT - 1 year ago

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

NEO

Fulgent Genetics: Growth Is Returning

Jun 6, 2024, 11:36 AM EDT - 1 year ago

Fulgent Genetics: Growth Is Returning

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

May 14, 2024, 4:05 PM EDT - 1 year ago

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

Fulgent Genetics, Inc. (FLGT) Q1 2024 Earnings Call Transcript

May 3, 2024, 11:43 AM EDT - 1 year ago

Fulgent Genetics, Inc. (FLGT) Q1 2024 Earnings Call Transcript

Fulgent Reports First Quarter 2024 Financial Results

May 3, 2024, 7:00 AM EDT - 1 year ago

Fulgent Reports First Quarter 2024 Financial Results

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

Apr 11, 2024, 4:05 PM EDT - 1 year ago

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:59 AM EST - 1 year ago

Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 1 year ago

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21, 2024, 7:20 AM EST - 1 year ago

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

jf152
jf152 Jul. 2 at 8:56 PM
$FLGT Where is $18???
1 · Reply
jf152
jf152 Jun. 28 at 3:27 PM
$FLGT where is this $18?
0 · Reply
Sexydream
Sexydream Jun. 23 at 1:43 PM
$FLGT 18s coming today. 17.50 very shortly after that. It will settle around low 17s/high 16s.
1 · Reply
AlexBo6
AlexBo6 Jun. 21 at 11:27 AM
$FLGT #Bullish , hell yeh..
0 · Reply
Sexydream
Sexydream Jun. 20 at 3:51 PM
$FLGT 19s are here. 17s coming soon folks. Will fill the 17.50 gap.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 17 at 12:25 PM
$FLGT Fulgent not mentioned here but it is a huge potential market. Not sure how much or when the newer ADC targeted drugs will also be used though. https://www.globenewswire.com/news-release/2025/03/27/3050697/28124/en/The-Global-Market-for-Paclitaxel-Injections-Presents-an-11-17-Billion-Revenue-Opportunity-by-2029-Analysis-of-Key-Players-Pfizer-BMS-Fresenius-Kabi-Oncology-Abbott-Labs-and-Viatris.html
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:50 PM
$FLGT The last thing I will say is that, yes, as the guys imply below, canceling the forward agreement does feel bullish. We will see.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:41 PM
$FLGT I wish Ming never entered into those forward agreements in the first place. Because he perhaps knew the likely future sequence of events regarding the fold-in of Pharma, and its eventual downward effect on the stock price. In my opinion, while legal, it just felt a bit like a conflict of interest. And calling his trust the ‘Dynasty Trust’ seems a little overbearing too.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:30 PM
$FLGT In Nov 2022, Fulgent paid to bring Pharma back into Fulgent Genetics. Remember that Ming had another agreement earlier, in June 2022 where his Trust received $44M for pledging 1M shares. Maybe ‘fleeced’ is the wrong word but Ming did ‘win’ vs. the bank.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:20 PM
$FLGT What you guys are missing is that Ming’s trust received $29M up front in cash from the bank in creating that Sep 2022 agreement. Ming totally fleeced the bank by canceling the agreement now for just $16.4M.
1 · Reply
jf152
jf152 Jun. 13 at 8:21 PM
$FLGT $16,446,960.00 was paid to cancel this contract.
0 · Reply
CrayP
CrayP Jun. 13 at 11:23 AM
$FLGT Not for nothing the settlement of Ming's forward variable contract was always a risk and overhang, but he cancelled the contract and settled in cash instead of 800K shares.
1 · Reply
Sexydream
Sexydream Jun. 12 at 8:07 PM
$FLGT hope you all enjoyed this colossal run to 21. LOL. Watch it come down now. 👍
1 · Reply
blahblahg
blahblahg Jun. 11 at 5:54 PM
$FLGT Hey folks, I recently wrote this intro on Fulgent Genetics for my Substack newsletter, please hit the subscribe button if you enjoy, and feel free to check out my other articles. https://unfairvalue.substack.com/p/fulgent-genetics-cash-rich-and-underappreciated?r=2ra1p4
0 · Reply
jf152
jf152 Jun. 10 at 1:48 PM
$FLGT
1 · Reply
Chairman5
Chairman5 Jun. 10 at 12:46 AM
$FLGT looks like straight to 30s
1 · Reply
theshortsqueezer2022
theshortsqueezer2022 Jun. 8 at 3:18 AM
$FLGT good job bulls. This is now heading to triple digits.
0 · Reply
Jerseyman2222000
Jerseyman2222000 Jun. 8 at 1:53 AM
$FLGT Hello Fulgent friends. I’ll be purchasing 500,000 shares in the next week or so. I hope everyone has been well.
1 · Reply
jf152
jf152 Jun. 6 at 9:18 PM
$FLGT Up 9.36% since this completely unjustified prediction @Sexydream
0 · Reply
jf152
jf152 Jun. 3 at 9:00 PM
$FLGT What gaps are being filled?
0 · Reply
jf152
jf152 Jun. 3 at 8:58 PM
$FLGT
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 3 at 4:02 PM
$FLGT If FID-007 fails, they could close the pharma division and then their share price should rise due to ending the negative EV that is based on current pharma cash burn. If FID-007 succeeds, the share price should rise. Win-Win!
0 · Reply